A 486th-place finish can look like the last seat on the bus, but Cedar’s 102% revenue growth from 2022 through 2025 is not nothing. Healthcare billing is a miserable, deeply entrenched corner of the economy where legacy systems have had decades to dig in. Growing at all while selling technology into health systems deserves a serious look, even if nobody should confuse a Deloitte Technology Fast 500 mention with a clean bill of health on the business.
A Modest Ranking With a Useful Signal
Cedar landed at No. 486 among 500 companies in Deloitte’s 2026 ranking, which measures percentage fiscal-year revenue growth over the 2022 to 2025 period. That placement matters because it keeps the chest-thumping in proportion. This was not a top-10 rocket ship or evidence that Cedar has solved healthcare finance. It was, however, a qualifying growth rate above 100% in a field where sales cycles can drag, implementation work is tedious, and buyers do not swap core revenue tools on a whim.
The list itself has a floor: eligible companies needed at least $50,000 in 2022 operating revenue, at least $5 million in 2025 operating revenue, proprietary technology contributing meaningfully to revenue, and growth of 50% or more. Those criteria establish a baseline, not a valuation or an earnings profile. Cedar has not disclosed its revenue dollars, profitability, retention, or customer concentration in these notes. Investors and sector watchers ought to resist filling those blanks with happy talk.
Kora Meets a Very Real Collection Problem
What makes the story worth watching is the problem Cedar says its Kora Platform addresses. Patients are becoming healthcare’s fastest-growing payer class, while much of the billing stack was built around insurers. That mismatch is painfully obvious to anyone who has received a baffling medical bill, then spent an afternoon trying to determine what is owed, when it is due, and whether help is available. Hospitals need collections; patients need clarity and options. The old machinery is lousy at both.
Cedar attributes its growth to adoption of Kora and execution by its team. Fair enough, but that is management’s explanation, not independent proof of cause and effect. The more tangible operating markers are substantial: Cedar says its technology draws on more than 1.5 billion patient interactions, has supported more than 63 million patients nationwide, and has processed over $13.6 billion in payments. Scale like that can improve product data and workflow knowledge. It can also create a big responsibility to handle outreach and financial-assistance pathways with care. This is healthcare, not a game of squeezing clicks out of shoppers.
Where the Thesis Gets Harder
The attractive version of the Cedar argument is straightforward. Health systems face pressure to collect more from individuals at lower cost, and an AI-driven platform that makes billing, payment plans, and assistance easier could become increasingly valuable. A platform that sits near payment flows may also enjoy sticky relationships once it is integrated into health-system operations. That is the upside case, and frankly it has more substance than another generic claim about AI changing everything.
But this market has land mines. Patient affordability is not an abstract conversion metric. Aggressive outreach, confusing options, or poor financial-assistance routing can damage trust quickly. Health systems also move carefully, procurement can be slow, and any vendor handling sensitive patient-finance interactions must perform consistently. Cedar’s large interaction count is encouraging, but it does not tell us satisfaction levels, collection yields, implementation costs, or whether growth is becoming easier or harder to sustain.
Recognition Is Not the Finish Line
Deloitte noted that nearly 70% of this year’s Fast 500 winners were repeat honorees and that private companies represented almost 80% of the list. That says the ranking is populated by firms still proving they can scale, not just established giants cruising on old market share. Cedar’s appearance puts it in that competitive current. Still, No. 486 is a reminder that growth rankings are relative snapshots, not a permanent moat.
The part I would watch is plain: can Cedar keep translating its payment scale and Kora adoption into durable health-system relationships while actually improving the patient experience? If the answer is yes, the company is aimed at a nasty, expensive inefficiency with real staying power. If growth merely reflects a temporary rush of implementations, the award will age like yesterday’s headline. For now, this is a credible operating signal, not a victory lap.